These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 25873248)

  • 61. Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode.
    Tignol J; Pujol-Domenech J; Chartres JP; Léger JM; Plétan Y; Tonelli I; Tournoux A; Pezous N
    Acta Psychiatr Scand; 1998 Feb; 97(2):157-65. PubMed ID: 9517912
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study.
    Arnold LM; Arsenault P; Huffman C; Patrick JL; Messig M; Chew ML; Sanin L; Scavone JM; Pauer L; Clair AG
    Curr Med Res Opin; 2014 Oct; 30(10):2069-83. PubMed ID: 24867298
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Milnacipran: a dual norepinephrine and serotonin reuptake pump inhibitor.
    Preskorn SH
    J Psychiatr Pract; 2004 Mar; 10(2):119-26. PubMed ID: 15330407
    [No Abstract]   [Full Text] [Related]  

  • 64. Contributions of change in clinical status parameters to Patient Global Impression of Change (PGIC) scores among persons with fibromyalgia treated with milnacipran.
    Geisser ME; Clauw DJ; Strand V; Gendreau MR; Palmer R; Williams DA
    Pain; 2010 May; 149(2):373-378. PubMed ID: 20332060
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Differential blockade of nerve injury-induced shift in weight bearing and thermal and tactile hypersensitivity by milnacipran.
    King T; Rao S; Vanderah T; Chen Q; Vardanyan A; Porreca F
    J Pain; 2006 Jul; 7(7):513-20. PubMed ID: 16814690
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms.
    Yoshida K; Takahashi H; Higuchi H; Kamata M; Ito K; Sato K; Naito S; Shimizu T; Itoh K; Inoue K; Suzuki T; Nemeroff CB
    Am J Psychiatry; 2004 Sep; 161(9):1575-80. PubMed ID: 15337646
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Milnacipran: serotonin-noradrenaline reuptake inhibitor approved for fibromyalgia may be a useful antidepressant.
    Keks NA; Hope J; Keogh S; Copolov DL
    Australas Psychiatry; 2018 Oct; 26(5):537-540. PubMed ID: 30198305
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The monoamine-mediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain.
    Obata H; Saito S; Koizuka S; Nishikawa K; Goto F
    Anesth Analg; 2005 May; 100(5):1406-1410. PubMed ID: 15845695
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency.
    Isaac MT; Isaac MB; Gallo F; Tournoux A
    Hum Psychopharmacol; 2003 Dec; 18(8):595-601. PubMed ID: 14696018
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Is milnacipran effective in treating pain in patients with fibromyalgia?
    Simon LS
    Nat Clin Pract Rheumatol; 2006 Mar; 2(3):126-7. PubMed ID: 16932669
    [No Abstract]   [Full Text] [Related]  

  • 71. Effects of milnacipran on cognitive flexibility following chronic stress in rats.
    Naegeli KJ; O'Connor JA; Banerjee P; Morilak DA
    Eur J Pharmacol; 2013 Mar; 703(1-3):62-6. PubMed ID: 23422875
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.
    Puech A; Montgomery SA; Prost JF; Solles A; Briley M
    Int Clin Psychopharmacol; 1997 Mar; 12(2):99-108. PubMed ID: 9219045
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Serotonin syndrome after administration of milnacipran for fibromyalgia.
    Yacoub HA; Johnson WG; Souayah N
    Neurology; 2010 Feb; 74(8):699-700. PubMed ID: 20177126
    [No Abstract]   [Full Text] [Related]  

  • 75. A comparative study of milnacipran and paroxetine in outpatients with major depression.
    Sechter D; Vandel P; Weiller E; Pezous N; Cabanac F; Tournoux A;
    J Affect Disord; 2004 Dec; 83(2-3):233-6. PubMed ID: 15555719
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Serotonin-noradrenaline reuptake inhibitors(SNRIs)].
    Ishigooka J
    Nihon Rinsho; 2001 Aug; 59(8):1523-9. PubMed ID: 11519152
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia.
    Ohta H; Oka H; Usui C; Ohkura M; Suzuki M; Nishioka K
    Arthritis Res Ther; 2012 Oct; 14(5):R217. PubMed ID: 23062189
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Fibromyalgia syndrome: which antidepressant drug should we choose.
    Littlejohn GO; Guymer EK
    Curr Pharm Des; 2006; 12(1):3-9. PubMed ID: 16454718
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pain management in fibromyalgia.
    Crofford LJ
    Curr Opin Rheumatol; 2008 May; 20(3):246-50. PubMed ID: 18388513
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study.
    Mease PJ; Clauw DJ; Trugman JM; Palmer RH; Wang Y
    J Pain Res; 2014; 7():679-87. PubMed ID: 25473309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.